 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| |
Executive
Team
Neal M. Farber, Ph.D.
Elkan Gamzu, Ph.D.
Daniel Katzman, M.Sc.
David Gwynne, Ph.D
Eyal S. Ron, Ph.D.
Board of Directors |
Advisors
Ross Baldessarini, M.D.
Teo Forsht Dagi, M.D.
Daniel Drubach, M.D.
Stan Goldstein
Esteban Fridman, M.D.
Pamela Hay, J.D.
Douglas Katz, M.D.
Daniel Tarsy, M.D.
Ross Zafonte, D.O.
George Zitnay, Ph.D.
|
|
| |
Executive Team |
|
| |
Neal
M. Farber, Ph.D., Chief Executive Officer
Dr. Farber has over 20 years experience in the biopharmaceutical
industry in areas of research and product development. As President
and CEO of Collgard Biopharmaceuticals, he raised $7 MM in a series
A financing; completed a $40 MM corporate deal with a medical device
company; initiated Phase I and II clinical trials in autoimmune
and cancer programs; and signed development agreements with the
NCI, EORTC, Mayo Clinic and the Walter Reed Army Hospital. Previously,
Dr. Farber held senior corporate development positions at Biogen,
Cubist Pharmaceuticals, and T Cell Sciences. Dr. Farber was a Helen
Hay Whitney Research Fellow at Harvard University and received his
PhD (Hammett Award) from Columbia University.
|
|
| |
Elkan
Gamzu, Ph.D., Chairman of the Board, Acting Head of Clinical Trials
Dr. Gamzu has worked in the biopharmaceutical industry since 1971,
in discovery with Hoffmann La Roche, in clinical management
and drug development with Warner-Lambert, where as VP, Drug Development had responsibility for the development of Cognex,
the first drug approved for Alzheimer's, and Neurontin. Dr. Gamzu served
as CEO of Cambridge Neuroscience and as Interim VP of Development Project Leadership for Millennium Pharmaceuticals.
He is a co-founder of BioPharmAnalysis, LLC, a company offering
due diligence services and currently serves as Principal of enERGetics,
LLC, a biopharmaceutical consulting company. Dr. Gamzu currently
serves the boards of directors of Pharmos Corp. (NASDAQ: PARS) and Neurotech S.A.
|
|
| |
Daniel Katzman M.Sc., President and Founder
Mr. Katzman has over ten years
of experience in the life sciences industry. Before founding NeuroHealing
he served as VP of Business Development at Oridion Medical Ltd,
a publicly traded company (Zurich SWX: ORIDN). By leading one of
Oridion’s two divisions, Mr. Katzman supervised clinical trials,
regulatory approval, intellectual property and marketing.
Additionally, he has been granted four US patents, has led a pivotal, multi-center
Phase III study and has obtained FDA approval for a drug-device
combination product which included an NDA and a 510(k). Mr. Katzman received his graduate degree in Biochemistry from Universidad Nacional de La Plata, Argentina.
|
|
| |
David Gwynne,Ph.D., Vice President, Business Development
Dr. Gwynne
has worked in the biopharmaceutical industry since 1984 holding
positions in both R&D and in business development. Dr. Gwynne has
led R&D teams at Allelix Biopharmaceuticals and at Cambridge NeuroScience.
In addition, Dr. Gwynne has held senior business development positions
at Cambridge NeuroScience, CeNeS, Cita Pharmaceuticals and, most recently,
as VP Business Development at Indevus Pharmaceuticals, where he completed
four corporate licensing deals. Dr. Gwynne has experience in several
therapeutic areas with emphasis on CNS disorders and urology.
Dr. Gwynne received his Ph.D. from McGill University.
|
|
| |
Eyal S. Ron, Ph.D., Senior Director of Formulation Development
Dr. Ron is an expert in the development of drugs, biomaterials
and drug delivery systems. He has contributed to the formation
of Cerebrotec, eNOS Pharmaceuticals, Focal, GelMed/Gel Sciences
and InfiMed. Under his leadership numerous products have been
developed and approved, including oral sustained release products
(PefusiaTM); implantable, biodegradable, sustained release devices
(Gliadel®, InFuse®, ProLease®); biodegradable sealants (FocalSeal®);
and transmucosal delivery systems. Dr. Ron is the author of over 100
papers, book chapters and abstracts, and the inventor of over 30 patents
mostly in the area of new indications for drugs, drug formulations,
drug delivery, and biomaterials. Dr. Ron holds a PhD in chemistry from
Brandeis and completed a post-doctoral fellowship at MIT under Robert Langer.
|
|
| |
Advisors |
|
| |
Ross
Baldessarini, M.D.
Dr. Baldessarini is Professor of Psychiatry and Neuroscience at Harvard Medical School,
Director of the Lab for Psychiatric Research and the Psychopharmacology Program at McLean Hospital (MGH).
He is widely known for research and teaching in psychopharmacology and general psychiatry.
He is the author of nearly 1,600 scientific publications and serves on the editorial boards
of several neuropharmacology journals.
|
|
| |
Teo
Forsht Dagi, M.D., M.P.H., F.A.C.S., F.C.C.M.
Dr. Dagi was trained in neurosurgery and neurophysiology at MGH and
Harvard Medical School. He has served as managing partner of Cordova Technology Partners. Dr. Dagi serves as a director
of privately and publicly held corporations in biotech, medical devices, healthcare and information technology. He is the
co-author of the book Penetrating Head Injuries.
|
|
| |
Daniel
Drubach, M.D.
Dr. Drubach is a Senior Associate Consultant in the Department of
Neurology and Psychiatry at the Mayo Clinic in Rochester, MN where
he leads the Coma Program. Dr. Drubach is a US board certified Neurologist
and Psychologist and authored the book The Brain Explained.
|
|
| |
Stan
Goldstein
Mr. Goldstein is the Chairman and Founder of Sleep HealthCenters; former President and CEO,
Premier Rehabilitation Centers, a privately owned provider of services
and support to persons with acquired brain injury and related neurological disorders.
|
|
| |
Esteban
Fridman, M.D., Founder
Dr. Fridman is a Board Certified
Neurologist in Argentina and former Fellow of the US National Institute
of Neurological Diseases and Stroke (NINDS), part of the National
Institutes of Health (NIH), Bethesda, MD. Dr. Fridman currently
serves as an extra-mural investigator for the NINDS. Dr. Fridman
also leads the Neurorehabilitation section at the FLENI Hospital,
a leading Argentinean institution specializing in neurosciences.
|
|
| |
Pamela
Hay, J.D.
Pamela Hay is a business development
and operations consultant for early stage biotechnology companies. She
was Chief Commercial Officer at Domantis Ltd from 2001 until its
acquisition by GSK in 2007, where she oversaw commercial development,
including completion of major alliances with Abbott and BMS and
additional deal negotiations that concluded the company’s purchase.
Previously, she was SVP, Corporate Development at Dyax Corp where
she was responsible for the negotiation of more than 60 licenses
and collaborations as well as the legal and IP functions. She has
also held senior legal positions at T Cell Sciences and Biogen.
Pamela has a JD from the University of Wisconsin and a BA in Biology from Cornell University.
|
|
| |
Douglas
Katz, M.D.
Dr. Katz is Medical Director of the Brain Injury Programs at Braintree
Rehabilitation Hospital and Associate Professor of Neurology at
Boston University School of Medicine. Dr. Katz is a co-author of "Brain Injury Medicine", the authoritative
texbook for this field of medicine.
|
|
| |
Daniel
Tarsy, M.D.
Dr. Tarsy serves as the Vice Chairman, Department of Neurology, Beth Israel Deaconess Medical Center
and is an Associate Professor of Neurology at Harvard Medical School.
He has extensive experience in phase II and III clinical trials in Parkinson’s disease
and related movement disorders.
|
|
| |
Ross
Zafonte, D.O.
Dr. Zafonte is the Vice President of Medical Affairs and Chair of the Dept. of PMR at Harvard Medical School
Before, Dr. Zafonte served as Professor and Chair of the Department of Physical Medicine and Rehabilitation
at the University of Pittsburgh School of Medicine. In addition to his leadership roles at the University of Pittsburgh,
Dr. Zafonte maintained a clinical practice in which he cared for patients with a wide variety of disabilities, including
traumatic brain injuries, spinal cord injuries, multiple sclerosis, compressive neuropathies, spasticity, and post
concussive musculoskeletal conditions. Dr. Zafonte is a pioneer in proposing the use of dopaminergic stimulants
for neurological low-level functioning patients. Dr. Zafonte is a co-author of "Brain Injury Medicine", the authoritative
texbook for this field of medicine.
|
|
| |
George
Zitnay, Ph.D.
Dr. Zitnay is Chairman of the National Brain Injury Research Treatment
and Training Foundation; Director of Virginia NeuroCare, Inc; Director
of the John Jane Brain Injury Center in Charlottesville, Virginia;
and Past President and CEO of the Brain Injury Association from
1991 to 1998.
|
|
 |
© 2003-2010, NeuroHealing
Pharmaceuticals Inc. All Rights Reserved. |
 |
|